Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacteremia | 3 | 2022 | 99 | 0.970 |
Why?
|
| Clostridium Infections | 3 | 2023 | 125 | 0.910 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 14 | 0.860 |
Why?
|
| Hypotension | 1 | 2022 | 70 | 0.820 |
Why?
|
| Publishing | 1 | 2022 | 90 | 0.810 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 255 | 0.800 |
Why?
|
| Public Health | 1 | 2022 | 129 | 0.790 |
Why?
|
| Fever | 5 | 2022 | 125 | 0.720 |
Why?
|
| Sepsis | 1 | 2022 | 306 | 0.650 |
Why?
|
| Pandemics | 2 | 2022 | 740 | 0.650 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 64 | 0.640 |
Why?
|
| Pneumonia, Necrotizing | 1 | 2017 | 1 | 0.600 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2019 | 27 | 0.580 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 263 | 0.580 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 73 | 0.550 |
Why?
|
| Neutrophils | 3 | 2020 | 307 | 0.480 |
Why?
|
| Child | 12 | 2023 | 6927 | 0.460 |
Why?
|
| Virulence Factors | 2 | 2010 | 108 | 0.440 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2009 | 5 | 0.430 |
Why?
|
| Anti-Bacterial Agents | 6 | 2023 | 746 | 0.430 |
Why?
|
| Hemolysin Proteins | 2 | 2009 | 34 | 0.420 |
Why?
|
| Bacterial Toxins | 2 | 2009 | 111 | 0.400 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 36 | 0.380 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 84 | 0.380 |
Why?
|
| Humans | 35 | 2023 | 86643 | 0.350 |
Why?
|
| Proteoglycans | 1 | 2010 | 121 | 0.350 |
Why?
|
| Membrane Transport Proteins | 1 | 2010 | 166 | 0.350 |
Why?
|
| Communicable Diseases | 1 | 2010 | 63 | 0.340 |
Why?
|
| Lung Diseases | 2 | 2009 | 263 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 508 | 0.340 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 21 | 0.340 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 28 | 0.340 |
Why?
|
| HIV Infections | 1 | 2017 | 772 | 0.320 |
Why?
|
| Actinomycosis | 1 | 2008 | 12 | 0.320 |
Why?
|
| Syndecans | 1 | 2007 | 4 | 0.320 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 231 | 0.310 |
Why?
|
| Drug Utilization | 2 | 2018 | 65 | 0.300 |
Why?
|
| Guideline Adherence | 2 | 2021 | 223 | 0.300 |
Why?
|
| Neoplasms | 1 | 2022 | 2898 | 0.290 |
Why?
|
| Critical Care | 2 | 2022 | 370 | 0.290 |
Why?
|
| Shock, Septic | 2 | 2023 | 102 | 0.280 |
Why?
|
| Health Personnel | 2 | 2021 | 202 | 0.280 |
Why?
|
| Adolescent | 9 | 2022 | 8981 | 0.280 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 154 | 0.280 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 1 | 0.270 |
Why?
|
| Paragonimiasis | 1 | 2005 | 1 | 0.270 |
Why?
|
| Appendicitis | 1 | 2006 | 62 | 0.270 |
Why?
|
| Child, Preschool | 10 | 2023 | 3612 | 0.260 |
Why?
|
| Cross Infection | 2 | 2017 | 141 | 0.260 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 636 | 0.240 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 66 | 0.230 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2379 | 0.230 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 23 | 0.230 |
Why?
|
| Inflammation | 2 | 2008 | 920 | 0.220 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 89 | 0.210 |
Why?
|
| Critical Pathways | 1 | 2022 | 35 | 0.210 |
Why?
|
| Hand Hygiene | 1 | 2021 | 10 | 0.200 |
Why?
|
| Inpatients | 2 | 2021 | 297 | 0.200 |
Why?
|
| Burns | 1 | 2023 | 131 | 0.200 |
Why?
|
| Infliximab | 2 | 2019 | 151 | 0.190 |
Why?
|
| Infection Control | 2 | 2021 | 115 | 0.190 |
Why?
|
| Neutropenia | 1 | 2020 | 215 | 0.180 |
Why?
|
| Leadership | 1 | 2021 | 134 | 0.180 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 7 | 0.170 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 25 | 0.170 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 34 | 0.170 |
Why?
|
| Syndecan-1 | 2 | 2009 | 13 | 0.170 |
Why?
|
| Expert Testimony | 1 | 2018 | 46 | 0.160 |
Why?
|
| Chagas Disease | 1 | 2018 | 3 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2022 | 319 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 21 | 0.160 |
Why?
|
| Logistic Models | 1 | 2022 | 1186 | 0.160 |
Why?
|
| Leishmaniasis | 1 | 2017 | 4 | 0.160 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2017 | 15 | 0.160 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 44 | 0.160 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 927 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2023 | 8489 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 6 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 76 | 0.150 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 28 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 426 | 0.150 |
Why?
|
| Meglumine | 1 | 2017 | 39 | 0.150 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 106 | 0.150 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 33 | 0.150 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2017 | 26 | 0.150 |
Why?
|
| HIV Antibodies | 1 | 2017 | 25 | 0.150 |
Why?
|
| Drug Overdose | 1 | 2018 | 65 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 143 | 0.140 |
Why?
|
| Vancomycin | 1 | 2017 | 72 | 0.140 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.140 |
Why?
|
| Sorbitol | 1 | 2016 | 6 | 0.140 |
Why?
|
| Blood Culture | 1 | 2016 | 11 | 0.140 |
Why?
|
| Foodborne Diseases | 1 | 2016 | 8 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 132 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 238 | 0.130 |
Why?
|
| Male | 12 | 2023 | 40965 | 0.130 |
Why?
|
| Social Media | 1 | 2016 | 79 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 826 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 146 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1851 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 142 | 0.120 |
Why?
|
| Epidermal Cyst | 1 | 2013 | 7 | 0.120 |
Why?
|
| Education, Medical | 1 | 2016 | 233 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 413 | 0.120 |
Why?
|
| Meningitis | 1 | 2013 | 20 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 878 | 0.110 |
Why?
|
| Physician's Role | 1 | 2015 | 179 | 0.110 |
Why?
|
| Escherichia coli | 1 | 2016 | 597 | 0.110 |
Why?
|
| Female | 11 | 2019 | 44532 | 0.110 |
Why?
|
| Animals | 7 | 2010 | 26582 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2013 | 180 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2015 | 329 | 0.100 |
Why?
|
| Infant | 4 | 2019 | 3046 | 0.100 |
Why?
|
| Aspirin | 2 | 2014 | 156 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 736 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2014 | 243 | 0.090 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2009 | 21 | 0.090 |
Why?
|
| Lung Injury | 1 | 2009 | 47 | 0.080 |
Why?
|
| Chemokines | 1 | 2008 | 73 | 0.080 |
Why?
|
| Enterotoxins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2020 | 99 | 0.080 |
Why?
|
| Tertiary Care Centers | 2 | 2019 | 94 | 0.080 |
Why?
|
| Adult | 3 | 2023 | 25648 | 0.080 |
Why?
|
| Brain Abscess | 1 | 2007 | 8 | 0.080 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2007 | 21 | 0.080 |
Why?
|
| United States | 5 | 2018 | 6672 | 0.080 |
Why?
|
| Leishmania | 2 | 2017 | 7 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1565 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2007 | 63 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 666 | 0.070 |
Why?
|
| Bronchi | 1 | 2007 | 229 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2601 | 0.070 |
Why?
|
| Risk Factors | 3 | 2023 | 5417 | 0.070 |
Why?
|
| Praziquantel | 1 | 2005 | 1 | 0.070 |
Why?
|
| Anthelmintics | 1 | 2005 | 6 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3092 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2501 | 0.060 |
Why?
|
| Chicago | 2 | 2019 | 1379 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1196 | 0.060 |
Why?
|
| Radiography | 1 | 2005 | 813 | 0.060 |
Why?
|
| Bandages | 1 | 2023 | 41 | 0.060 |
Why?
|
| Hand Disinfection | 1 | 2021 | 17 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2021 | 30 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 10 | 0.050 |
Why?
|
| Mice | 3 | 2009 | 11352 | 0.050 |
Why?
|
| Critical Illness | 1 | 2023 | 294 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2020 | 220 | 0.050 |
Why?
|
| Molecular Typing | 1 | 2019 | 17 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 159 | 0.040 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 53 | 0.040 |
Why?
|
| Medical Audit | 1 | 2018 | 41 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 67 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 154 | 0.040 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 256 | 0.040 |
Why?
|
| Public Health Practice | 1 | 2017 | 11 | 0.040 |
Why?
|
| Public Health Administration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 399 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 379 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2017 | 65 | 0.040 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 103 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 62 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2016 | 72 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 121 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 5976 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 185 | 0.040 |
Why?
|
| Drug Costs | 1 | 2017 | 62 | 0.040 |
Why?
|
| Food Service, Hospital | 1 | 2016 | 4 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 702 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 151 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 684 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 839 | 0.030 |
Why?
|
| Nasopharynx | 1 | 2015 | 47 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 294 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 849 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 454 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1805 | 0.030 |
Why?
|
| Viruses | 1 | 2015 | 78 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 911 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 219 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 148 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 43 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2014 | 177 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1991 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 695 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1577 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 2767 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 572 | 0.020 |
Why?
|
| Physicians | 1 | 2018 | 673 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2894 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2010 | 90 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Craniotomy | 1 | 2007 | 88 | 0.020 |
Why?
|
| Drainage | 1 | 2007 | 157 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1014 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 152 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1047 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1540 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 7993 | 0.020 |
Why?
|
| Cytokines | 1 | 2008 | 776 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1863 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 1170 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 1924 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 1195 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3241 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 25028 | 0.010 |
Why?
|